<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>How to treat <z:hpo ids='HP_0001903'>anemia</z:hpo> in the <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is controversial </plain></SENT>
<SENT sid="1" pm="."><plain>Many health care systems refuse to fund erythropoietin on grounds of health economics </plain></SENT>
<SENT sid="2" pm="."><plain>A new paper on the effect of <z:hpo ids='HP_0001903'>anemia</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> on cardiac remodeling has suggested that a higher treatment threshold level for <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> should be introduced </plain></SENT>
<SENT sid="3" pm="."><plain>This would have an impact of the calculation of risk/benefits </plain></SENT>
</text></document>